AbCellera Biologics, Inc. (ABCL)

AbCellera Biologics Inc. stock has been impacted by several events in the past six months. The company reported an EPS of -$0.19 in Q3 2025, missing analysts' expectations. Wall Street Zen upgraded AbCellera from a "sell" rating to a "hold" rating on January 12, 2026. Leerink Partners downgraded AbCellera Biologics from a "strong-buy" to a "hold" rating on November 7, 2025, and reaffirmed a "market perform" rating with a $4.00 price objective. Weiss Ratings restated a "sell (d-)" rating on October 8, 2025. On January 13, 2026, shares traded down 5.6% during mid-day trading, and over the past six months, the stock has seen a 3.39% change.

There is no direct indication of significant demand seasonality for AbCellera Biologics' products and services. Demand is primarily driven by ongoing research, clinical trial progress, and partnerships with pharmaceutical companies, rather than predictable seasonal consumer patterns. The revenue model relies on fees for its antibody discovery platform and future success-tied payments, which are not inherently seasonal.

AbCellera Biologics Inc. is a clinical-stage biotechnology company in Vancouver, Canada, specializing in antibody therapeutics. It operates in the Health Care sector, utilizing a technology platform that integrates biology, computation, and engineering to develop antibody-based medicines. Its product pipeline includes ABCL635 for vasomotor symptoms, ABCL575 for atopic dermatitis, and ABCL688 for an autoimmune disease. The company also collaborates with partners like Eli Lilly, Pfizer, and Moderna.

AbCellera Biologics Inc. is headquartered in Vancouver, British Columbia, Canada, and has invested significantly in its corporate and manufacturing sites there.

AbCellera Biologics holds a "Hold" consensus rating from analysts, with an average rating score of 2.29, and a news sentiment score of 0.70. Its reputation has been influenced by its perceived involvement in the "AI x biotech trade," but there have been discussions about a "deteriorating premium amid mounting expenses" and a high short interest in the stock. The company has faced significant R&D losses and a stalled partnership program and pipeline, leading to a $57 million loss in Q3 2025.

AbCellera Biologics Inc. has a diverse ownership structure. Institutional shareholders hold approximately 34.75% to 61.4% of the stock, insiders own around 19.04% to 44.84%, and retail investors hold about 20.41% to 52.41%. Major institutional owners include Baker Bros. Advisors Lp, SMCWX - SMALLCAP WORLD FUND INC Class A, Capital World Investors, Baillie Gifford & Co, Two Sigma Investments, Lp, Two Sigma Advisers, Lp, ArrowMark Colorado Holdings LLC, BlackRock, Inc., Renaissance Technologies Llc, Morgan Stanley and UBS Asset Management. The largest individual shareholder is Carl L. G. Hansen, who owns 19.04% of the company. Thermopylae Holdings Ltd is another significant insider owner.